Previous close | 27.53 |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
Moderna CEO Stéphane Bancel joins Yahoo Finance Live to discuss fourth quarter earnings for the company, global COVID-19 vaccine equity, and the outlook for production amid Russia-Ukraine tensions.
DGAP-News: Moderna, Inc. / Key word(s): Miscellaneous24.02.2022 / 17:20 The issuer is solely responsible for the content of this announcement.EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European UnionAnnouncement follows CHMP's previous decision to adopt a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include adoles
Oppenheimer Analyst Hartaj Singh joins Yahoo Finance Live to discuss fourth quarter earnings for Moderna.